Taletrectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor, primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene fusions/mutations. It exerts its therapeutic effect by precisely inhibiting the activity of abnormal gene proteins and blocking the proliferation signaling pathways of tumor cells. It is suitable for patients who have developed resistance to first-generation ALK inhibitors or are intolerant to such agents, and its use must be strictly guided by genetic testing results and under the supervision of a qualified physician.
Mechanism of Action
Targeted Therapy: Acting on ALK/ROS1 gene mutations, it inhibits the abnormal kinase activity and blocks downstream oncogenic signaling pathways, including the MAPK and PI3K pathways.
Overcoming Drug Resistance: It may retain therapeutic efficacy following resistance to first-generation ALK inhibitors (e.g., crizotinib), particularly demonstrating sensitivity to certain resistance mutations such as the G1202R mutation.
Indications and Administration Guidelines
Eligible Patient Populations
Patients with advanced NSCLC confirmed to be ALK/ROS1-positive via genetic testing.
Patients with disease progression after treatment with first-generation ALK inhibitors or those who are intolerant to such therapies.
Usage Restrictions
Confirmation of the mutation status through pathological testing is mandatory; the drug must not be administered blindly.
Precautions for Use
Dosage Adjustment
The dosage should be dynamically adjusted based on adverse reactions (e.g., hepatic impairment, cardiac rhythm abnormalities). Regular monitoring of liver function, electrocardiography (ECG), and other relevant indicators is required.
Drug-Drug Interactions
Concomitant use with strong CYP3A4 inducers (e.g., rifampicin) should be avoided, as this may reduce the therapeutic efficacy of taletrectinib.
Common Adverse Reactions and Management
Mild to Moderate Reactions
Fatigue, nausea, edema, and other symptoms, which can generally be alleviated through dietary modifications or symptomatic management.
Visual disturbances (e.g., photopsia): Patients should avoid driving or engaging in activities requiring precise manual operation.
Severe Reactions
Interstitial lung disease (manifested as aggravated dyspnea and cough): Immediate drug discontinuation and prompt medical attention are required.
Bradycardia (manifested as dizziness, syncope): Electrocardiographic monitoring is necessary, and appropriate dosage adjustments should be made.
Medical Guidance and Medication Instructions
Genetic Testing as a Prerequisite
Confirmation of ALK/ROS1 status via tissue or blood testing is mandatory prior to initiating treatment.
Strict Compliance with Medical Advice
The dosage and treatment course should be individualized, and patients must not increase, decrease, or discontinue the medication without professional guidance.
Regular Follow-Up Visits
Efficacy and adverse reactions should be assessed every 2 to 3 months, and abnormal indicators must be managed in a timely manner.
As a targeted therapeutic agent, taletrectinib must be used in strict accordance with the guidance of professional oncologists. Patients are strongly advised not to purchase the drug or modify the treatment regimen on their own.
